From: AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
Patients (%) | 186 | (100.0) |
---|---|---|
Age at diagnosis [years] | ||
 Median (range) | 57 | (26–85) |
Progression-free survival [months] | ||
 Median (range) | 16 | (1–48) |
 Number of recurrencies (%) | 106 | (57.0) |
Overall survival [months] | ||
 Median (range) | 24 | (1–49) |
 Number of deaths (%) | 54 | (29.0) |
Histology (%) | ||
 Serous | 164 | (88.2) |
 Non-serous | 22 | (11.8) |
FIGO (%) | ||
 II | 9 | (4.8) |
 III | 148 | (79.6) |
 IV | 29 | (15.6) |
Grading (%) | ||
 1 | 6 | (3.2) |
 2 | 43 | (23.1) |
 3 | 137 | (73.7) |
Residual disease after initial surgery (%) | ||
 None | 132 | (71.0) |
  ≤ 1 cm | 34 | (18.3) |
  > 1 cm | 20 | (10.8) |
Type of chemotherapy (%, 30 missing [16.1Â %]) | ||
 Adjuvant | 124 | (66.7) |
 Neoadjuvant | 15 | (8.1) |
 Intraperitoneal | 17 | (9.1) |
Response to first-line chemotherapy (%, 1 missing) | ||
 Responder | 138 | (74.2) |
 Non-Responder | 47 | (25.3) |